NCT07179159 - Efficacy and Safety of 14-Day Vonoprazan-Based Dual Therapy Versus Quadruple Therapy for Helicobacter Pylori Eradication: A Multicentre, Non-Inferiority Randomized Controlled Trial | Biotech Hunter

Enrollment

372

Participants

Timeline

Start Date

September 9, 2025

Primary Completion Date

August 31, 2026

Study Completion Date

December 31, 2026

Conditions

HELICOBACTER PYLORI INFECTIONS

Interventions

DRUG

14-day vonoprazan-amoxicillin dual therapy

vonoprazan 20mg bid + amoxicillin 1000mg bid

DRUG

14-day vonoprazan-amoxicillin-levofloxacin-bismuth quadruple therapy

vonoprazan 20mg bid + amoxicillin 1000mg bid + levofloxacin 500mg qd + bismuth 220mg bid

DRUG

14-day vonoprazan-amoxicillin-clarithromycin-bismuth quadruple therapy

vonoprazan 20mg bid + amoxicillin 1000mg bid + clarithromycin 500mg bid + bismuth 220mg bid

Trial Locations (1)

Unknown

Qilu Hospital of Shandong University, Jinan

All Listed Sponsors

collaborator

Longkou People's Hospital

UNKNOWN

collaborator

Qingdao Jimo People's Hospital

OTHER

collaborator

Shandong University of Traditional Chinese Medicine

OTHER

collaborator

Dezhou Hospital Qilu Hospital of Shandong University

OTHER

collaborator

Zibo Maternal and Child Health Hospital

UNKNOWN

collaborator

Guanxian People's Hospital

UNKNOWN

collaborator

Yantai Zhifu Hospital

UNKNOWN

collaborator

The 2nd People's Hospital of Dongying City

UNKNOWN

collaborator

Qilu Hospital of Shandong University

OTHER

lead

Yanqing Li

OTHER